Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
BCR-ABL1 fusion
Cancer:
Acute Lymphocytic Leukemia
Drug Class:
Tyrosine kinase inhibitor
Regimen:
CVAD (cyclophosphamide + dexamethasone injection + doxorubicin hydrochloride + vincristine)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
HEMO 2020
Title:
TYROSINE KINASE INHIBITORS PLUS HYPER-CVAD FOR THE FRONTLINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Published date:
11/26/2020
Excerpt:
In this study we observed that a high response rate can be achieved in predominantly young adults with Ph+ ALL treated with the Hyper-CVAD plus TKI.
DOI:
10.1016/j.htct.2020.10.316
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login